keyword
MENU ▼
Read by QxMD icon Read
search

Myeloma transplant

keyword
https://www.readbyqxmd.com/read/27905003/new-agents-in-hsc-mobilization
#1
REVIEW
Mélanie J Domingues, Susan K Nilsson, Benjamin Cao
Mobilized peripheral blood (PB) is the most common source of hematopoietic stem cells (HSC) for autologous transplantation. Granulocyte colony stimulating factor (G-CSF) is the most commonly used mobilization agent, yet despite its widespread use, a considerable number of patients still fail to mobilize. Recently, a greater understanding of the interactions that regulate HSC homeostasis in the bone marrow (BM) microenvironment has enabled the development of new molecules that mobilize HSC through specific inhibition, modulation or perturbation of these interactions...
November 30, 2016: International Journal of Hematology
https://www.readbyqxmd.com/read/27904448/mobilization-with-cyclophosphamide-reduces-the-number-of-lymphocyte-subpopulations-in-the-leukapheresis-product-and-delays-their-reconstitution-after-autologous-hematopoietic-stem-cell-transplantation-in-patients-with-multiple-myeloma
#2
Matevz Skerget, Barbara Skopec, Darja Zontar, Peter Cernelc
BACKGROUND: Autologous hematopoietic stem cell transplantation is considered the standard of care for younger patients with multiple myeloma. Several mobilization regimens are currently used, most commonly growth factors alone or in combination with chemotherapy. The aim of our study was to investigate the differences in lymphocyte subpopulation counts between three different mobilization regimens on collection day, in the leukapheresis product and on day 15 after autologous hematopoietic stem cell transplantation...
December 1, 2016: Radiology and Oncology
https://www.readbyqxmd.com/read/27894207/when-to-recommend-a-second-autograft-in-patients-with-relapsed-myeloma
#3
Dimitrios C Ziogas, Evangelos Terpos, Meletios A Dimopoulos
In the current evolving landscape of myeloma therapies, no recommended salvage strategy exists for patients with relapsed multiple myeloma (MM) after initial successful autologous stem cell transplantation (ASCT) and therapeutic options extend from conventional chemotherapy and novel agents to second autologous and allogeneic transplants. In this article, we summarize the documented evidence about the utilization of second ASCT in patients with relapsed MM after a primary auto-graft and discuss the correct timing for such a salvage approach, the individual characteristics of patients who will benefit more, as well as the therapeutic role of second ASCT in the modern era of forthcoming anti-myeloma treatments...
November 28, 2016: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/27893836/prognostic-value-of-serum-free-light-chains-measurements-in-multiple-myeloma-patients
#4
José Luis García de Veas Silva, Carmen Bermudo Guitarte, Paloma Menéndez Valladares, Johanna Carolina Rojas Noboa, Krysta Kestler, Rafael Duro Millán
BACKGROUND: The outcome for patients with Multiple Myeloma (MM) is highly variable, therefore, the existence of robust and easy to determine prognostic markers is extremely important for an efficient management of these patients. Presently, there is a debate about the role of the serum free light chains (sFLC) in the prognosis of MM patients both at diagnosis and after treatment. The aim of this study is to evaluate in a cohort of newly diagnosed MM patients from the Southern area of Spain, the prognostic value of sFLC both at baseline and after treatment...
2016: PloS One
https://www.readbyqxmd.com/read/27888768/multiple-myeloma-treatment-at-relapse-after-autologous-stem-cell-transplantation-a-practical-analysis
#5
REVIEW
F Malard, J L Harousseau, M Mohty
Over the past decade, significant advances have been made in the field of multiple myeloma. Introduction of the so-called novel agents, proteasome inhibitors (PI) and immunomodulatory drugs (IMiD), and improved supportive care have resulted in significantly better outcome. Standard first line treatment in fit patients include PI and IMiD based induction, high dose melphalan with autologous hematopoietic stem cell transplantation (ASCT) and consolidation/maintenance. However, despite these progresses MM remains incurable for the majority of patients and most patients will relapse...
November 15, 2016: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/27885144/treatment-of-multiple-myeloma-in-a-heart-transplant-recipient-focus-on-the-immunomodulatory-effects-of-lenalidomide
#6
Lola Xie, Bartosz Jozwik, Phillip Weeks, L Maximilian Buja, Robert Brown, Sriram Nathan, Keshava Rajagopal, Christina Paruthi, Biswajit Kar, Pranav Loyalka, Indranee Rajapreyar
Malignancy following solid organ transplant remains a significant threat to the survival of cardiac transplant recipients. Plasma cell dyscrasias including multiple myeloma have been encountered in this population, and medication treatments traditionally used to treat these disorders demonstrate immunomodulatory effects that may have implications on the transplanted allograft. Lenalidomide is an immunomodulatory agent that has been used to treat plasma cell disorders, including light-chain amyloidosis (AL) and multiple myeloma, and represents such a class of medications in which the risks and benefits in the solid organ transplant population remain to be fully elucidated...
November 24, 2016: Progress in Transplantation
https://www.readbyqxmd.com/read/27881052/prognostic-value-of-lactate-dehydrogenase-in-chinese-patients-with-newly-diagnosed-transplant-eligible-multiple-myeloma
#7
Beihui Huang, Jin Lu, Xiaotao Wang, Yang Xiao, Ying Zhao, Hongming Huang, Junru Liu, Meilan Chen, Jingli Gu, Shiwen Yuan, Dong Zheng, Yonghua Li, Xiaojun Huang, Juan Li
No abstract text is available yet for this article.
November 23, 2016: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/27873176/palonosetron-aprepitant-and-dexamethasone-for-prevention-of-nausea-and-vomiting-after-high-dose-melphalan-in-autologous-transplantation-for-multiple-myeloma-a-phase-ii-study
#8
Atsushi Isoda, Rie Saito, Fuminori Komatsu, Yuki Negishi, Noriyasu Oosawa, Tetsuya Ishikawa, Yuri Miyazawa, Morio Matsumoto, Morio Sawamura, Akihiro Manaka
Chemotherapy-induced nausea and vomiting (CINV) is a significant side effect in multiple myeloma (MM) patients receiving high-dose melphalan treatment followed by autologous stem cell transplantation (ASCT). We evaluated the efficacy and safety of a triple antiemetic combination of palonosetron, aprepitant, and low-dose dexamethasone in 24 MM patients who received melphalan conditioning (100 mg/m(2) on days 1-2) before ASCT (on day 4). Intravenous palonosetron (0.75 mg on day 1), oral aprepitant (125 mg on day 1; 80 mg on days 2-4), and intravenous dexamethasone (6...
November 21, 2016: International Journal of Hematology
https://www.readbyqxmd.com/read/27869809/absence-of-spontaneous-response-improvement-beyond-day-100-after-autologous-stem-cell-transplantation-in-multiple-myeloma
#9
C Fernández de Larrea, J Dávila, I Isola, E M Ocio, L Rosiñol, R García-Sanz, M T Cibeira, N Tovar, M Rovira, M V Mateos, J S Miguel, J Bladé
The response evaluation after autologous stem-cell transplantation (ASCT) is usually performed at day +100 in patients with multiple myeloma (MM). A recent report suggests that improvement in the response can be observed beyond day +100. The aim of the present study has been to evaluate the rate of improved response and outcome beyond day +100 after ASCT, with and without maintenance therapy. One hundred and forty-four patients who underwent single ASCT with chemosensitive disease and achieved less than CR at day 100 post ASCT were evaluated...
November 21, 2016: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/27864218/second-primary-malignancies-in-multiple-myeloma-an-overview-and-imwg-consensus
#10
REVIEW
P Musto, K C Anderson, M Attal, P G Richardson, A Badros, J Hou, R Comenzo, J Du, B G M Durie, J San Miguel, H Einsele, W M Chen, L Garderet, G Pietrantuono, J Hillengass, R A Kyle, P Moreau, J J Lahuerta, O Landgren, H Ludwig, A Larocca, A Mahindra, M Cavo, A Mazumder, P L McCarthy, A Nouel, S V Rajkumar, A Reiman, E R Serra, O Sezer, E Terpos, I Turesson, S Usmani, B M Weiss, A Palumbo
BACKGROUND: Therapeutic advancements following the introduction of autologous stem cell transplantation and 'novel' agents have significantly improved clinical outcomes for patients with multiple myeloma (MM). Increased life expectancy, however, has led to renewed concerns about the long-term risk of second primary malignancies (SPMs). This review outlines the most up-to-date knowledge of possible host-, disease-, and treatment-related risk factors for the development of SPMs in patients with MM, and provides practical recommendations to assist physicians...
November 17, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27864161/maintenance-versus-induction-therapy-choice-on-outcomes-after-autologous-transplantation-for-multiple-myeloma
#11
Robert F Cornell, Anita D'Souza, Adetola A Kassim, Luciano J Costa, Racquel D Innis-Shelton, Mei-Jie Zhang, Jiaxing Huang, Muneer Abidi, Jack Aiello, Gorgun Akpek, Asad Bashey, Qaiser Bashir, Jan Cerny, Raymond Comenzo, Miguel Angel Diaz, César Freytes, Robert Peter Gale, Siddhartha Ganguly, Mehdi Hamadani, Shahrukh Hashmi, Leona Holmberg, Nasheed Hossain, Rammurti T Kamble, Mohamed Kharfan-Dabaja, Tamila Kindwall-Keller, Robert Kyle, Shaji Kumar, Hillard Lazarus, Cindy Lee, Angelo Maiolino, David I Marks, Kenneth Meehan, Joe Mikhael, Rajneesh Nath, Taiga Nishihori, Richard F Olsson, Muthalagu Ramanathan, Ayman Saad, Sachiko Seo, Saad Usmani, David Vesole, Ravi Vij, Dan Vogl, Baldeep M Wirk, Jean Yared, Amrita Krishnan, Tomer Mark, Yago Nieto, Parameswaran Hari
Bortezomib (V), lenalidomide (R), cyclophosphamide (C) and dexamethasone (D) are components of the most commonly used modern doublet (RD, VD) or triplet (VRD, CVD) initial induction regimens prior to autologous hematopoietic cell transplantation (AHCT) for multiple myeloma (MM) in the US. In this study we evaluated 693 patients receiving "upfront" AHCT after initial induction therapy with modern doublet or triplet regimens using data reported to the Center for International Blood and Marrow Transplant Research from 2008-2013...
November 15, 2016: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/27863757/is-it-feasible-to-use-granulocyte-colony-stimulating-factor-alone-to-mobilize-progenitor-cells-in-multiple-myeloma-patients-induced-with-a-cyclophosphamide-thalidomide-and-dexamethasone-regimen
#12
Edvan de Queiroz Crusoe, Fabiana Higashi, Gracia Aparecida Martinez, José Carlos Barros, Marcelo Bellesso, Marina Rossato, Ana Cinira F Marret, Carlos Sérgio Chiattone, Vania Tietsch de Moraes Hungria
BACKGROUND: Cyclophosphamide plus thalidomide as induction for multiple myeloma patients eligible for autologous stem cell transplantation may be a limiting factor for cell mobilization. The minimum acceptable mobilized peripheral blood stem cell count to prevent deleterious effects during transplantation is 2.0×10(6) CD34(+) cells/kg. Combining other treatments to granulocyte-colony stimulating factor, such as cyclophosphamide, could overcome the mobilization limitation. The objective of this study was to assess the number of CD34(+) cells mobilized using granulocyte-colony stimulating factor with and without cyclophosphamide after induction with cyclophosphamide, thalidomide and dexamethasone...
October 2016: Revista Brasileira de Hematologia e Hemoterapia
https://www.readbyqxmd.com/read/27863756/herpes-zoster-after-autologous-hematopoietic-stem-cell-transplantation
#13
Kelli Borges Dos Santos, Rafaela Souto E Souza, Angelo Atalla, Abrahão Elias Hallack-Neto
BACKGROUND: The autologous hematopoietic stem cell transplantation procedure involves immunosuppression of the patient. Thus, the patient has an elevated risk for several diseases, such as infections with the varicella-zoster virus. Prevention protocols have been proposed based on the use of acyclovir from the first day of conditioning, and maintaining this drug for 30-100 days after the procedure or for as much as one year. The objective of this work was to evaluate the incidence of herpes zoster after autologous transplantations related to the early suspension of acyclovir...
October 2016: Revista Brasileira de Hematologia e Hemoterapia
https://www.readbyqxmd.com/read/27863752/hematopoietic-stem-cell-mobilization-for-autologous-transplantation-in-multiple-myeloma-patients-previously-exposed-to-cyclophosphamide-thalidomide-and-dexamethasone-is-granulocyte-colony-stimulating-factor-alone-enough
#14
https://www.readbyqxmd.com/read/27862330/predictors-of-inferior-clinical-outcome-in-patients-with-standard-risk-multiple-myeloma
#15
Talha Badar, Samer Srour, Qaiser Bashir, Nina Shah, Gheath Al-Atrash, Chitra Hosing, Uday Popat, Yago Nieto, Robert Z Orlowski, Richard Champlin, Muzaffar H Qazilbash
INTRODUCTION: Outcome of patients with standard-risk (SR) multiple myeloma (MM) has improved; however, subsets of patients do worse than expected. We sought to identify the factors associated with inferior outcome. METHODS: We evaluated 51 patients with SR MM that received upfront autologous hematopoietic stem cell transplantation (auto-HCT) after induction and had a progression-free survival (PFS) of ≤18 months. RESULTS: The median age of patients was 61 yr...
November 9, 2016: European Journal of Haematology
https://www.readbyqxmd.com/read/27859769/association-between-complete-response-and-outcomes-in-transplant-eligible-myeloma-patients-in-the-era-of-novel-agents
#16
Helgi van de Velde, Anil Londhe, Ataman Ozlem, Helen L Johns, Stephen Hill, Emma Landers, Jesse A Berlin
OBJECTIVES: Achieving complete response (CR) has been linked to improved progression-free (PFS) and overall (OS) survival in myeloma. A meta-analysis was conducted to investigate whether this holds true in the era of novel agents (bortezomib, lenalidomide, thalidomide). METHODS: 24 studies in newly diagnosed patients undergoing autologous stem cell transplantation (ASCT) that reported associations between responses and long-term outcomes (PFS/OS rates post-ASCT by response, or hazard ratios with 95% confidence intervals from Cox models) were identified and analyzed...
November 16, 2016: European Journal of Haematology
https://www.readbyqxmd.com/read/27859332/patients-outcome-after-rescue-plerixafor-administration-for-autologous-stem-cell-mobilization-a-single-center-retrospective-analysis
#17
Silvia Spoerl, Robert Peter, Dagmar Wäscher, Katharina Götze, Mareike Verbeek, Christian Peschel, Angela M Krackhardt
BACKGROUND: Plerixafor is predominantly used for patients mobilizing inadequate stem cell numbers for autologous transplantation after stimulation with granulocyte-colony-stimulating factor (G-CSF). STUDY DESIGN AND METHODS: We here report on 300 patients undergoing stem cell mobilization with G-CSF, among them 36 poor mobilizers (CD34+ cell counts < 50 × 10(6) /L blood) receiving G-CSF alone and 49 receiving G-CSF in combination with plerixafor for rescue intervention...
November 18, 2016: Transfusion
https://www.readbyqxmd.com/read/27856369/outcomes-of-maintenance-therapy-with-bortezomib-post-autologous-stem-cell-transplantation-for-patients-with-multiple-myeloma
#18
Dharshan Sivaraj, Michael M Green, Zhiguo Li, Anthony D Sung, Stefanie Sarantopoulos, Yubin Kang, Gwynn D Long, Mitchell E Horwitz, Richard D Lopez, Keith M Sullivan, David A Rizzieri, Nelson J Chao, Cristina Gasparetto
Comprehensive recommendations for maintenance therapy post-autologous stem cell transplantation (ASCT) for patients with multiple myeloma (MM) have yet to be defined. Bortezomib has been utilized as maintenance therapy after ASCT, but data attesting to the safety and efficacy of this agent compared to lenalidomide in the post-ASCT setting are limited. Therefore we retrospectively analyzed the outcomes of 102 MM patients who received maintenance therapy with bortezomib post-ASCT at Duke University's Adult Bone Marrow Transplant Clinic (ABMT) between 2005 and 2015...
November 14, 2016: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/27847663/extramedullary-plasmacytoma-mimicking-pancreatic-cancer-an-unusual-presentation
#19
Daniela Sciancalepore, Sergio Musci, Maria Rosaria Fracella, Grazia D'Alesio, Azzurra Sportelli, Giuseppe Ingravallo, Angelo Vacca, Roberto Ria
Multiple myeloma is a plasma cell tumor that homes to and expands in the bone marrow and that, despite the new available drugs, remains incurable. Extramedullary plasmacytoma is a not frequent manifestation during the natural history of multiple myeloma and is frequently associated with plasma cell bone marrow infiltration. The most common locations for an EMP include the gastrointestinal tract, pleura, testis, skin, peritoneum, liver, endocrine glands, and lymph nodes. Primary involvement of the gallbladder fossa is exceedingly rare...
2016: Case Reports in Oncological Medicine
https://www.readbyqxmd.com/read/27843120/bortezomib-thalidomide-dexamethasone-and-panobinostat-for-patients-with-relapsed-multiple-myeloma-muk-six-a-multicentre-open-label-phase-1-2-trial
#20
Rakesh Popat, Sarah R Brown, Louise Flanagan, Andrew Hall, Walter Gregory, Bhuvan Kishore, Matthew Streetly, Heather Oakervee, Kwee Yong, Gordon Cook, Eric Low, Jamie Cavenagh
BACKGROUND: Panobinostat (a pan histone deacetylase inhibitor) is approved in combination with bortezomib and dexamethasone for patients with relapsed multiple myeloma who have received two or more previous lines of therapy. We aimed to improve the safety of this combination and investigate efficacy by incorporating low-dose thalidomide, using sub-cutaneous weekly bortezomib, and determining the maximum tolerated dose of panobinostat in this regimen. METHODS: We did a phase 1/2, multicentre, open-label trial (MUK six) at four hospitals in the UK, enrolling patients with relapsed, or relapsed and refractory, multiple myeloma aged at least 18 years, with an Eastern Cooperative Oncology Group performance status of 2 or less who had previously received 1-4 lines of therapy...
November 11, 2016: Lancet Haematology
keyword
keyword
41539
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"